NCT02965118

CAPTAIN-AD: Clinical Study of AmorePacific's TRPV1 Antagonist in Atopic Dermatitis

Multi Center, Randomized, Double-blind, Placebo-controlled Parallel-group, Phase III Clinical Trial to Evaluate the Safety and Efficacy of PAC-14028 Cream in Mild to Moderate Atopic Dermatitis Patients

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 240 (actual)
• Sponsor: Amorepacific Corporation · Industry
• Sex: All
• Age: 12 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a phase III study to investigate the safety and efficacy of PAC-14028 cream in Atopic Dermatitis patients.

Detailed description

PAC-14028 cream 1.0% or placebo will be treated to Mild to Moderate Atopic Dermatitis patients twice daily for 8 weeks.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	PAC-14028 cream 1.0%	topical application
DRUG	PAC-14028 cream Vehicle	topical application

Timeline

• Start date: 2016-11-01
• Primary completion: 2018-11-01
• Completion: 2018-11-01
• First posted: 2016-11-16
• Last updated: 2018-11-20

Locations

1 site across 1 country: South Korea